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Altered Serum Thyrotropin Concentrations in Dogs with Primary
Hypoadrenocorticism before and during Treatment
C.E. Reusch, F. Fracassi , N.S. Sieber-Ruckstuhl, W.A. Burkhardt, N. Hofer-Inteeworn,
C. Schuppisser, M. Stirn, R. Hofmann-Lehmann, and F.S. Boretti
Background: Thyrotropin (TSH) can be increased in humans with primary hypoadrenocorticism (HA) before glucocorti-
coid treatment. Increase in TSH is a typical ﬁnding of primary hypothyroidism and both diseases can occur concurrently
(Schmidt’s syndrome); therefore, care must be taken in assessing thyroid function in untreated human patients with HA.
Objective: Evaluate whether alterations in cTSH can be observed in dogs with HA in absence of primary hypothyroidism.
Animals: Thirty dogs with newly diagnosed HA, and 30 dogs in which HA was suspected but excluded based on a normal
ACTH stimulation test (controls) were prospectively enrolled.
Methods: cTSH and T4 concentrations were determined in all dogs and at selected time points during treatment (pred-
nisolone, ﬂudrocortisone, or DOCP) in dogs with HA.
Results: cTSH concentrations ranged from 0.01 to 2.6 ng/mL (median 0.29) and were increased in 11/30 dogs with HA;
values in controls were all within the reference interval (range: 0.01–0.2 ng/dL; median 0.06). There was no diﬀerence in T4
between dogs with increased cTSH (T4 range 1.0-2.1; median 1.3 lg/dL) compared to those with normal cTSH (T4 range 0.5-
3.4, median 1.4 lg/dL; P=0.69) and controls (T4 range 0.3-3.8, median 1.8 lg/dL; P=0.35). After starting treatment, cTSH nor-
malized after 2–4 weeks in 9 dogs and after 3 and 4 months in 2 without thyroxine supplementation.
Conclusions and Clinical Relevance: Evaluation of thyroid function in untreated dogs with HA can lead to misdiagnosis
of hypothyroidism; treatment with glucocorticoids for up to 4 months can be necessary to normalize cTSH.
Key words: ACTH; Addison; Cortisol; cTSH; Hypothyroidism.
Hypoadrenocorticism (HA) is a disease in whichadrenocortical steroid hormone secretion falls
below the physiologic requirement of the animal. The
vast majority of aﬀected dogs have primary HA, which
usually results from immune-mediated destruction of
the adrenal cortex, terminating in an absolute deﬁciency
of glucocorticoids and mineralocorticoids.1,2 Due to the
lack of the negative feedback on the pituitary gland, an
increase in plasma concentrations of endogenous ACTH
is typically observed.3–5
Human patients with primary HA can have thyroid-
stimulating hormone (TSH; thyrotropin) concentrations
that are increased despite normal T4 concentrations
before initiating glucocorticoid treatment.6 As TSH will
normalize after glucocorticoid supplementation, the
increase has been explained by a lack of the inhibitory
eﬀect of cortisol on the secretion of TSH.7–9 Increased
TSH concentrations in patients with HA are also
observed in those patients that suﬀer from concomitant
primary hypothyroidism, known as type II autoimmune
polyendocrine syndrome or Schmidt’s syndrome. To
avoid a misdiagnosis of hypothyroidism, it has been
recommended that serum TSH and thyroid hormone
concentrations should be interpreted in light of the
patient’s cortisol concentrations and that thyroid func-
tion is better assessed after glucocorticoid treatment has
been started.6,7
Although rare, polyglandular autoimmune syndromes
do exist in veterinary medicine also, and concomitant
primary hypothyroidism and HA occur in dogs.10–12 To
the authors’ knowledge, cTSH concentrations have not
yet been systematically evaluated in dogs with HA.
However, it would be important to know whether
increased cTSH concentrations can be observed before
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HA treatment, as has been described in human patients.
An increased cTSH is considered to be rather rare in
euthyroid dogs, except in the recovery phase from a
nonthyroidal illness (NTI),13,14 meaning that a high
TSH is rather speciﬁc for the diagnosis of primary
hypothyroidism, especially in combination with a
decreased T4. Therefore, this ﬁnding could easily lead
to a misdiagnosis of hypothyroidism and an unneces-
sary, lifelong thyroxine treatment.
Thus, the aim of this study was to evaluate cTSH
concentrations in dogs with HA before starting gluco-
corticoid treatment. Further, these results will be com-
pared to those of dogs in which HA has been excluded,
based on a normal ACTH stimulation test. In addition,
we wanted to evaluate cTSH concentrations in
dogs with HA during treatment with gluco- and
mineralocorticoids.
Materials and Methods
Animals
Thirty client-owned dogs presented between December 2010
and May 2016 with newly diagnosed, naturally occurring HA
were prospectively enrolled in the study. Work-up included com-
plete blood count, serum biochemical proﬁle, urinalysis, ACTH
stimulation test, measurement of plasma endogenous ACTH
(eACTH), and abdominal ultrasonography. HA was conﬁrmed
by an insuﬃcient ACTH-stimulated serum cortisol concentration
(<2 lg/dL).
Primary HA was diagnosed on the basis of abnormal serum
sodium and potassium concentrations or increased plasma eACTH
concentrations. Dogs with iatrogenic causes of HA (eg, previous
steroid or trilostane treatment) were excluded from the study.
Thirty dogs with diseases mimicking HA, diagnosed between
November 2013 and December 2015, were prospectively enrolled
in the study. All dogs had initially been suspected of having HA
but were ﬁnally determined to have a diﬀerent disease; all had
post-ACTH serum cortisol concentrations ≥4.5 lg/dL. Diseases
mimicking HA were associated with clinical signs and/or labora-
tory ﬁndings routinely seen in dogs with HA, for example, vomit-
ing, diarrhea, weakness, lethargy, hyperkalemia, hyponatremia, or
some combination of these.
All procedures were oﬃcially approved and conducted in accor-
dance with guidelines established by the Animal Welfare Act of
Switzerland (permission number: 133/2013). In addition, informed
consent was obtained from the dog owners.
Analytical Procedures
For the ACTH stimulation test, blood samples were taken
before and 60 min after intravenous or intramuscular injection of
5 lg/kg synthetic ACTH.a For the determination of plasma
eACTH, blood was collected, before ACTH application, into
chilled EDTA-coated tubes placed on ice and centrifuged at 4°C
within 30 min. For the determination of cortisol, T4, and cTSH
concentration, serum was harvested by low-speed centrifugation
after clot retraction at room temperature. All samples were stored
at 20°C until assayed. Plasma eACTH concentrations were
determined by a 2-site solid-phase chemiluminescent immunomet-
ric assay,b previously validated for dogs.15,16 Serum cortisol
concentrations were measured by a competitive immunoassay.c
The intra-assay coeﬃcients of variation were 10.0 and 6.3% at
cortisol levels of 2.7 and 18.9 lg/dL, respectively. The sensitivity
of the assay was 0.2 lg/dL. Serum cTSH concentrations were
measured by use of a solid-part, 2-site chemiluminescent enzyme
immunometric assay.d The intra-assay coeﬃcients of variation
were 5.0, 4, and 3.8% at TSH levels of 0.20, 0.50, and 2.6 ng/
mL, respectively. The interassay coeﬃcients of variation were 6.3
and 8.2% at TSH levels of 0.16 and 2.8 ng/mL, respectively. The
sensitivity of the assay was 0.03 ng/mL; upper limit of the refer-
ence range was 0.5 ng/mL. Serum T4 concentrations were deter-
mined with a homologous solid-phase, chemiluminescent enzyme
immunoassay.e The intra-assay and interassay coeﬃcients of vari-
ation (T4 concentrations between 0.65 and 11.9 lg/dL; each con-
centration tested in duplicate twice daily over the course of
20 days) were 3.9–10.8 and 5.2–13.8%, respectively, reference
range, 1.0–2.9 lg/dL.
Statistical Analyses
Statistical analysis was performed by commercial softwarefg
using nonparametric tests. Data are expressed as median and
range. Diﬀerences between groups were tested by the use of the
Kruskal-Wallis H test and Mann-Whitney U-test with a Dunn’s
post-test. Friedman‘s repeated-measures test and Dunn’s multiple
comparisons test were used for evaluating cTSH and T4 concen-
trations at the diﬀerent time points. Correlation was determined
by Spearman rank correlation coeﬃcient.
For cTSH values below the detection limit, the mean between 0
and the detection limit of 0.03 ng/mL (corresponding to 0.015 ng/mL)
was entered for statistical analysis, and for plasma eACTH con-
centrations >1,250, 1,251 pg/mL was used. Values of P < 0.05
were considered signiﬁcant.
Results
Dogs
In the 30 dogs with HA, age ranged from 0.5 to
12 years (median, 5 years) and body weight from 1.8 to
75.2 kg (median, 13.2 kg). There were 10 males (4 cas-
trated) and 20 females (19 spayed). There was no diﬀer-
ence in age between male and female dogs. The HA
group consisted of 23 purebred and 7 mixed-breed dogs.
Twenty-seven of the 30 dogs had abnormal serum
electrolyte concentrations, 2 of the 3 dogs with normal
electrolytes had high plasma eACTH concentrations, and
in 1 of those 3, eACTH had not been determined. From
the 20 dogs, in which eACTH had been determined, 19
had a high eACTH. All 30 dogs were treated with pred-
nisolone; starting dose in the hospital ranged between 0.5
and 1 mg/kg IV, q6 to q12 h, depending on the severity
of the signs for a duration of 12–48 h, depending on the
clinical condition of the dog. Three dogs received
prednisolone only, due to normal serum electrolytes.
Fourteen of them received DOCPj injection with a start-
ing dose of 1.5–2 mg/kg SC every 28 days in addition to
the prednisolone, and 13 dogs additionally to the predni-
solone received ﬂudrocortisonei at a starting dose of
0.01 mg/kg q 12 h. In all dogs, the prednisolone dose
was reduced over several weeks after discharge to a ﬁnal
dose of 0.05–0.1 mg/kg per day. Median (range) follow-
up time of the dogs was 6.4 months (0.5–67.4). In dogs
with a follow-up of less than 3 months, either the
referring practitioner or the owners were contacted to
conﬁrm good clinical control of the disease.
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In the dogs with diseases mimicking HA, age ranged
from 1 to 9 years (median, 5 years) and body weight from
1.7 to 44 kg (median, 11.3 kg). There were 14 males (7
castrated) and 16 females (9 spayed). This group consisted
of 28 purebred dogs and 2 mixed-breed dogs. There was
no signiﬁcant diﬀerence in age (P = 0.38), body weight
(P = 0.76), or sex (P = 0.45) between dogs with HA and
the non-HA dogs. The ﬁnal diagnoses reached were acute
gastroenteritis (8), intoxication (5), chronic gastroenteritis
(4), psychogenic polyuria/polydipsia (1), acute colitis (2),
pancreatitis (2), idiopathic epilepsy (2), laryngeal paralysis
(1), kidney injury (1), insulinoma (1), idiopathic megae-
sophagus (1), no ﬁnal diagnosis reached (2).
Serum cTSH and Serum T4 Concentrations at the
Time Point of Diagnosis
At the time of diagnosis of HA, cTSH ranged from
0.01 to 2.6 ng/mL (median 0.29) and was above the ref-
erence interval in 11 of 30 dogs. There was no diﬀerence
in body weight (P = 0.8) and electrolyte concentrations
(K; P = 0.052 and Na; P = 0.44) between dogs with
increased and normal cTSH values. However, increased
cTSH concentrations were only observed in female dogs
(1 intact).
T4 concentrations at the time of diagnosis of HA
ranged from <0.5 to 3.8 (median 1.8) and was below
the reference interval in only 2 dogs, both of which had
cTSH within the reference interval. Dogs with cTSH
concentrations above the reference interval did not have
lower T4 concentrations compared to those with normal
cTSH (P = 0.69; Fig 1).
Serum cTSH and Serum T4 Concentrations During
Treatment of HA
Compared with the time of diagnosis, there was a sig-
niﬁcant (P = 0.0004) decrease in cTSH concentrations
at the ﬁrst recheck after 0.5–1 month of treatment, with
a range (median) of 0.01–1.3 ng/mL (0.13 ng/mL)
(Fig 2). In all but 2 dogs with cTSH, concentrations
above the reference interval cTSH have been normalized
at that time point. In 1 dog, cTSH had increased from
0.83 to 1.3 ng/mL at the ﬁrst recheck. A TSH stimula-
tion test was performed to exclude hypothyroidism,
which turned out to be normal, and 4 months after
diagnosis of HA, cTSH had decreased to 0.4 ng/mL
(without thyroxine supplementation). In the other dog,
cTSH had increased from 0.56 to 0.63 ng/mL at the
ﬁrst recheck. However in this dog also, cTSH decreased
to 0.4 ng/mL after 3 months of treatment. Neither of
the 2 dogs had clinical signs suggestive of hypothy-
roidism and in both clinical signs were well controlled
with HA treatment alone.
T4 concentrations at all time points after the start of
treatment were not signiﬁcantly diﬀerent from before
treatment (P = 0.56).
Serum cTSH of the Dogs with Disease Mimicking
HA
Median (range) cTSH concentrations in dogs with
disease mimicking HA were 0.06 ng/dL (0.01–0.2),
which was signiﬁcantly lower (<0.0001) than those of
the dogs with HA at the time point of diagnosis. None
of them showed values above the upper limit of the ref-
erence interval (Table 1).
Fig 1. Scatter plot comparing serum T4 concentrations in dogs
with hypoadrenocorticism (HA) and serum cTSH concentrations
above the reference interval (n = 11) with those with normal serum
cTSH concentrations (n = 19). The horizontal bars represent the
median of each group. There was no signiﬁcant diﬀerence between
the 2 groups (P = 0.69).
Fig 2. Change in serum cTSH concentrations of the 30 dogs with
HA at the time point of diagnosis (0), 0.5–1 month, and 3–
4 months after starting HA treatment. Dotted line represents the
upper limit of the laboratory reference interval for serum cTSH
concentration (0.5 ng/mL).
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Serum T4 Concentrations of the Dogs with HA
Compared with those of Dogs with Disease Mimicking
HA
There was no statistically signiﬁcant diﬀerence in T4
concentrations between dogs with disease mimicking
HA and those with HA (P = 0.35). The results of both
groups are summarized in Table 1.
Discussion
In the present study, we were able to show that 37%
of dogs with HA had cTSH concentrations typically
seen in cases of hypothyroidism. By comparison, none
of the dogs with diseases mimicking HA had increased
cTSH concentrations. To our knowledge, this phe-
nomenon has not yet been described in dogs. Interest-
ingly, 1 of our dogs with clinical signs of weakness had
been treated with thyroxine for several weeks by a pri-
vate veterinarian. Despite thyroxine supplementation
(10 lg/kg q12 h), clinical signs did not improve and the
owner stopped the treatment. Two months thereafter,
the dog was referred to our clinic and at that time point
showed an increased cTSH concentration of 1.06 ng/mL
and a normal T4 of 2.3 lg/dL with no other abnormal
ﬁndings in CBC and serum biochemistry. The dog was
monitored during several months and cTSH remained
increased with a T4 in the reference range. Clinical signs
were unchanged and samples ﬁnally were sent to Michi-
gan State University, Diagnostic Center for Population
and Animal Health. Increased cTSH with T4 and fT4
within the reference range could be conﬁrmed. Thy-
roglobulin, and T4 and T3 autoantibodies were negative.
The owner decided not to proceed with any diagnostic
work-up and declined trial treatment with thyroxine at a
dosage of 20 lg/kg q12 h. Not until 9 months after the
ﬁrst presentation, diagnosis of HA could be made as at
that time point, potassium had increased to 6.0
(reference interval 4.3–5.3 mmol/L), with a normal Na
155 mmol/L (reference interval 152–159). An ACTH
stimulation test conﬁrmed the diagnosis (basal cortisol
<0.2 lg/dL and post-ACTH cortisol <0.2, eACTH
616 pg/mL). Treatment with prednisolone and
ﬂudrocortisone led to a normalization of the clinical
signs and cTSH concentration within only 2 weeks.
cTSH remained within the reference interval during a
follow-up period of 4 years, without thyroxine supple-
mentation. This case is similar to what was reported in a
human patient with untreated primary cortisol deﬁciency
who had been supplemented with thyroxine for 6 years.
Despite thyroxine supplementation, cTSH had remained
increased.17 After cortisol replacement and withdrawal
of the thyroxine, TSH normalized, conﬁrming that
hypothyroidism had been misdiagnosed. Based on these
observations, it can be stated that hypothyroidism can
easily be misdiagnosed in individuals with untreated HA
and that care should be taken in assessing thyroid
function not only in human patients but also in dogs
with HA.
The inﬂuence of cortisol concentrations on the serum
concentration of TSH has been intensively studied in
humans, and a direct relationship between low concen-
trations of corticosteroid concentration and increased
TSH secretion was demonstrated. In healthy humans
given metyrapone to block cortisol synthesis, signiﬁ-
cantly higher TSH concentrations compared to baseline
levels were observed.9 Further, patients with HA
showed a gradual rise in TSH over a 48-h hydrocorti-
sone withdrawal period.18 Variable infusion rates of
hydrocortisone led to higher TSH concentrations during
low cortisol states and reestablishment of a physiologic
cortisol pattern led to signiﬁcant decreases in TSH con-
centrations during the day in these patients.8,19 The
authors concluded that mildly increased TSH concen-
trations are possible if patients have not taken their
daily hydrocortisone dose. They speculated that a cer-
tain minimum or even a precise threshold of cortisol
concentration at physiologic concentrations would be
necessary for TSH suppression. In our study also, we
demonstrated that higher corticoid concentrations lead
to a suppression of cTSH secretion, as serum concentra-
tions decreased to within the reference interval in all
dogs after glucocorticoid supplementation. Therefore,
we assume that the TSH excess before adrenal replace-
ment can be attributed to an enhancement of TSH
release due to the chronic cortisol deﬁciency.
Table 1. Median, range, reference interval of serum cTSH, serum T4, plasma eACTH, and serum cortisol (before
and after ACTH stimulation) concentrations of dogs with HA and with diseases mimicking HA and the P values of
the diﬀerences between the 2 groups. For cTSH values below the detection limit, the mean between 0 and the detec-
tion limit of 0.03 ng/mL (corresponding to 0.015 ng/mL) was entered for statistical analysis, and for plasma eACTH
concentrations >1,250, 1,251 pg/mL was used.
Reference Interval
Dogs with
Hypoadrenocorticism
Dogs with Diseases
Mimicking HA
P valueRange Median Range Median
cTSH (ng/mL) <0.5 0.015–2.62 0.22 0.015–0.2 0.06 <0.0001
T4 (lg/dL) 1.3–2.9 0.5–4.4 1.4 <0.5–3.8 1.8 0.35
eACTH (pg/mL) 18.3–1,251 1,250 <10–45.8 18.3 <0.0001
Baseline Cortisol (lg/dL) >2.0 <0.2–0.7 <0.2 <0.2–13.8 1.5 <0.0001
Post-ACTH Cortisol (lg/dL) <0.2–0.6 <0.2 4.7–41.1 11.7 <0.0001
HA, hypoadrenocorticism
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In contrast to our study, in which only female dogs
had increased cTSH concentrations, studies in human
patients have found that both male and female patients
with HA may have increased TSH concentrations.
Based on the present data, we cannot explain our obser-
vation. All except 1 of the 11 female dogs were spayed,
therefore it could also be hypothesized that cTSH is
aﬀected by ovariectomy as has been shown for FSH
and LH: Both of these pituitary hormones have been
shown to increase after gonadectomy in female and
male dogs.20,21 However, as cTSH concentrations
remained unaﬀected in male dogs after gonadectomy,22
this hypothesis seems less likely. As case numbers were
low, the dominance of female animals could merely be
a statistical phenomenon. The latter assumption is con-
ﬁrmed by the following observation: a signiﬁcant
cTSH increase in male and female dogs has been
described in dogs with hypercortisolism during corti-
sol-lowering treatment with trilostane.23 This indicates
that if the glucocorticoid eﬀect on TSH is diminished,
an increase in TSH can be observed, independent of
the animal’s sex. We did see a signiﬁcant decrease in
cTSH after starting treatment with prednisolone,
not only in those dogs with increased cTSH concentra-
tions, but also in the majority of our other dogs
with cTSH within the reference interval, further con-
ﬁrming a sex-independent inﬂuence of cortisol on TSH
concentrations.
Taken together, glucocorticoids seem to play an
important role in the hypothalamus-pituitary-thyroid
axis, although to our knowledge, the exact molecular
mechanisms involved in the regulation of TSH release
by glucocorticoids are up to now unknown. Moreover,
one interesting question still remains, namely, why only
some of the dogs with HA have high cTSH concentra-
tions while others do not. It could be a matter of dura-
tion of the cortisol deﬁciency or a matter of disease
severity; however, this must remain speculative because
a shortcoming of the present study is that disease sever-
ity and duration of clinical signs were not systematically
assessed and documented. Clearly, what we also cannot
exclude based on our data is that the one or the other
of the dogs with high cTSH had subclinical hypothy-
roidism. This has been hypothesized in human medi-
cine: some human patients with Addison’s disease are
assumed to have chronic autoimmune thyroiditis that is
responsible for the increase in TSH.6,24 This is based on
the ﬁnding of serologic markers of thyroiditis in some
of these patients. Subclinical hypothyroidism associated
with immune-mediated thyroiditis, high serum TSH,
and normal thyroid hormone concentrations is well
documented in people. And even a relatively low dose
of glucocorticoid replacement can decrease the intensity
of the antithyroid autoimmune response to the point
that TSH will normalize.25 What speaks in favor of this
aspect is that in most of our dogs with high cTSH, T4
was normal and not increased which one could expect
due to the pituitary-thyroid feedback physiology.
Unfortunately, markers of autoimmune thyroiditis have
not been determined in the present study but are
underway.
As mentioned above, none of the dogs with diseases
mimicking HA had increased cTSH concentrations,
although almost 30% of them had T4 below the refer-
ence interval. Inﬂuence of NTI on T4 and cTSH concen-
trations has been studied by several authors14,26–28 and
frequency of low T4 concentrations is comparable
between the diﬀerent studies and ours. However, discrep-
ancies exist concerning the cTSH concentrations with
high cTSH values observed in 3–8% of the cases.14,27
Interestingly, the combination of a low T4 and fT4
together with a high cTSH seems to be even less com-
mon in dogs with NTI.13,14,27,28 From human medicine,
there is evidence that nonthyroidal disease can decrease
TSH secretion,29 and only in the recovery phase of NTI,
temporary increases in TSH concentrations are observed.
An increase in TSH has also been described in veterinary
medicine.13,14 In our study, as far as assessable, none of
the dogs was in the recovery phase of a disease. There-
fore, this might be one explanation for the diﬀerences in
the prevalence of high cTSH observed between the diﬀer-
ent studies. However, also in dogs with hypothyroidism,
occurrence of increased cTSH concentrations is highly
variable between diﬀerent studies, ranging from 25 to
40%. Several explanations in this setting, for example,
suppression of pituitary TSH secretion by concurrent dis-
ease or drug administration, and inability of the current
TSH assay to detect all isoforms of circulating TSH,
might also explain diﬀerent frequency of increased cTSH
concentrations in dogs with NTIs.
In summary, because there were several dogs with
cTSH concentrations typically seen in hypothyroidism,
care must be taken in evaluating thyroid function in
dogs with untreated HA. A minimum of 2 weeks of glu-
cocorticoid treatment seems to be necessary to normal-
ize cTSH concentrations. On the other hand, detection
of an increased cTSH concentration in a dog with
weakness should lead every veterinarian to consider HA
as a diﬀerential diagnosis.
Footnotes
a Synacthen, Novartis Pharma Schweiz AG, Bern, Switzerland
b DPC Immulite 1000, Siemens Schweiz AG, Zurich, Switzerland,
ACTH
c DPC Immulite 1000, Siemens Schweiz AG, Zurich, Switzerland,
canine cortisol
d DPC Immulite 1000, Siemens Schweiz AG, Zurich, Switzerland,
canine TSH
e DPC Immulite 1000, canine total T4
f SPSS, Statistical Package for the Social Science, Software Packets
for Windows, version 21
g GraphPad Prism 6, GraphPad Software, San Diego, CA
h Percorten V, Novartis Animal Health US, Greensboro, NC
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